TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04481035
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
Study: NCT02523235
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
Study: NCT01494155
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
Study: NCT00215540
Drug: Lucinactant 175 mg/kg
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
Study: NCT00215540
Drug: Lucinactant 90 mg/kg
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
Study: NCT00025376
Drug: PS-341
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04007224
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
Study: NCT02433041
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 0.005mg/kg at induction of anesthesia
Study: NCT02433041
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
Study: NCT02433041
Drug: Haloperidol + Ketamine
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
Study: NCT02433041
Drug: Saline solution (NaCl 0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo being used in one of the four groups
Study: NCT00303537
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03831984
Drug: 0,1% sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
Study: NCT02696564
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
Study: NCT00663429
Drug: Atiprimod
Normalized name: Atiprimod
DrugBank: Atiprimod (DB05513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 14 days on / 14 days off; 30mg capsules
Study: NCT00210600
Drug: PROCRIT (Epoetin alfa)
Normalized name: epoetin alfa Injection [Procrit]
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02062996
Drug: Oxymetazoline
Normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00032890
Drug: chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01815528
Drug: Catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10
Study: NCT04119453
Drug: Rivoceranib
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT00170833
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01313494
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast tablets
Study: NCT01313494
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
Study: NCT02479971
Drug: Normal saline irrigation
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
Study: NCT03861871
Drug: Fenfluramine Hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
Study: NCT02636101
Drug: Calcipotriol/betamethasone dipropionate gel
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical treatment of psoriasis plaques located on the body
Study: NCT02604550
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
Study: NCT02604550
Drug: Naprosyn 500 mg
Normalized name: Naprosyn 500 MG Oral Tablet
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naprosyn 500 mg will be taken twice daily.
Study: NCT01270386
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 750 mg p.o. once daily
Study: NCT02400866
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00185640
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
Study: NCT04447534
Drug: Chloroquine or hydroxychloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine or hydroxychloroquine
Study: NCT00185640
Drug: Anti-thymocyte globulin (ATG)
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
Study: NCT00185640
Drug: Mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
Study: NCT00185640
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day
Study: NCT02747797
Drug: Lucitanib
Normalized name: Lucitanib
DrugBank: Lucitanib (DB11845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg orally daily
Study: NCT02938949
Drug: alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00570349
Drug: Nitrogen
Normalized name: Nitrogen
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
Study: NCT03202537
Drug: dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexlansoprazole treatment for Gastroesophageal Reflux symptoms
Study: NCT03830203
Drug: Actemra(EU-licensed)
Normalized name: Actemra
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg
Study: NCT03707639
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study: NCT01390714
Drug: E3710
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration.
Study: NCT01390714
Drug: E3710
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration.
Study: NCT00273702
Drug: N-Acetyl Cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00577018
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg o.d.
Study: NCT00577018
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
Study: NCT01368107
Drug: interleukin 7
Normalized name: Interleukin 7 glycosylated
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
Study: NCT01368107
Drug: interleukin 7
Normalized name: Interleukin 7 glycosylated
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
Study: NCT01368107
Drug: interleukin 7
Normalized name: Interleukin 7 glycosylated
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
Study: NCT00829088
Drug: AZD2066
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose oral solution
Study: NCT01021488
Drug: enoxaparin only
Normalized name: Enoxaparin only product
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
Study: NCT03156907
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
Study: NCT03347344
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg will be administered (per os) twice a day
Study: NCT01870804
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01004601
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
Study: NCT01004601
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
Study: NCT01870674
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02096068
Drug: Dexmedetomidine (Dexdor®)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
Study: NCT02096068
Drug: 0.9% Sodium Chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
Study: NCT03625310
Drug: Sodium Fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03625310
Drug: Sodium Fluoride with TCP
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03625310
Drug: Sodium Fluoride with CXP
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03625310
Drug: Sodium Fluoride with CPP-ACP
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00785213
Drug: Rosiglitazone 4 mg Tablets
Normalized name: rosiglitazone 4 MG
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
Study: NCT00785213
Drug: Rosiglitazone 4 mg Tablets
Normalized name: rosiglitazone 4 MG
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
Study: NCT00785213
Drug: Quinine Sulfate 324 mg Capsules
Normalized name: quinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
Study: NCT02468128
Drug: Sebacoyl Dinalbuphine Ester
Normalized name: lutein esters
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular injection 2mL/vial (75mg/mL)
Study: NCT00148382
Drug: ATL-962
Normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03742882
Drug: CC-90001
Normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90001
Study: NCT04078737
Drug: Ticagrelor and Aspirin
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg
Study: NCT04078737
Drug: Clopidogrel and Aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day
Study: NCT00574249
Drug: Calcipotriol/Betamethasone Ointment
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Study: NCT01734252
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
Study: NCT02007044
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00496002
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00496002
Drug: Adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02162680
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162680
Drug: bacteriostatic normal saline (BNS)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00805090
Drug: Sporanox
Normalized name: Sporanox
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg
Study: NCT00038038
Drug: 18F-fluoromisonidazole
Normalized name: (18F)-Fluoride
DrugBank: Misonidazole (DB11716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
Study: NCT03258424
Drug: PTI-428
Normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTI-428 or placebo will be given QD for 14 days.
Study: NCT03994744
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Sintilimab (1200mg/3weeks)
Study: NCT03994744
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.
Study: NCT00324389
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04944303
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
Study: NCT00232596
Drug: Retigabine
Normalized name: retigabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
Study: NCT04325113
Drug: levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient satisfaction and pain score using a visual anagogic scale (VAS)
Study: NCT04538365
Drug: Triclosan 0.5 % Topical Solution
Normalized name: triclosan 0.5 % Topical Solution
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study: NCT04538365
Drug: propanolol
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study: NCT00813696
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
Study: NCT00813696
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
Study: NCT00947726
Drug: CeraVe
Normalized name: CeraVe
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using OTC cream on foot twice daily for two weeks.
Study: NCT03119623
Drug: sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
Study: NCT03119623
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enalapril 5mg, titrated up to 10mg po BID
Study: NCT01953432
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
Study: NCT02186847
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.